Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, November 19, 2026

Lynx1 suppression reopens the window for effective rehabilitation after stroke in mice

 Is their ANYONE ANYWHERE  in the stroke medical world that will ENSURE  human testing gets done? I guess not, NO ONE FUCKING CARES ABOUT STROKE SURVIVORS!

Lynx1 suppression reopens the window for effective rehabilitation after stroke in mice



Abstract

Rehabilitation is an effective and reliable approach for promoting motor recovery after stroke. However, its efficacy decreases during the transition from the subacute to the chronic phase after stroke, posing a major barrier to complete functional recovery. This limited efficacy during the chronic phase is believed to result from declining neural plasticity. However, the molecular and cellular mechanisms regulating neural plasticity and its temporal changes after stroke remain unclear. To address this gap, we established a focal ischemic stroke mouse model that allows causal interrogation of the mechanisms responsible for the reduced efficacy of rehabilitation in the chronic phase. Using this model, we identified Lynx1, an endogenous negative allosteric modulator of nicotinic acetylcholine receptors, as a negative regulator of post-stroke neural plasticity. Lynx1 expression in layer 5 pyramidal neurons was transiently down-regulated and returned to normal levels in the peri-infarct area. Longitudinal intravital imaging revealed that Lynx1 suppression promoted synaptic clustering with increased dendritic spine turnover in the peri-infarct area, an emerging structural basis for memory formation. As anticipated, Lynx1 suppression improved spontaneous motor recovery and the efficacy of rehabilitation in the chronic phase after stroke. Furthermore, we developed a Lynx1-targeting antisense oligonucleotide and found that its administration during the chronic phase after stroke enhanced the efficacy of rehabilitation. These findings suggest that dendritic spine dynamics in the peri-infarct area are a key determinant of rehabilitation responsiveness through the regulation of clustered spine formation and that Lynx1 may represent a promising therapeutic target for augmenting dendritic plasticity after stroke.

No comments:

Post a Comment